# Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies

- Source: PR Newswire General Business
- Published: 2026-11-02T14:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/brise-pharmaceuticals-announces-global-license-agreement-with-abbvie-to-advance-the-next-generation-of-migraine-therapies-302925660.html
- Canonical: https://groundlevelnews.com/story/brise-pharmaceuticals-announces-global-license-agreement-with-abbvie-t-0b5c4c/

BEIJING, Nov. 2, 2026 /PRNewswire/ -- Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for discovery...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire General Business._